Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a <i>PCM1-JAK2</i> Fusion Gene

30 Apr 2013

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 23630205
DOI: 10.1200/jco.2012.46.4370

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a <i>PCM1-JAK2</i> Fusion GenePMID 23630205Read ↗

Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2–positive chronic eosinophilic leukemiaSemantic proximity Read ↗

Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.Semantic proximity Read ↗

Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genesSemantic proximity Read ↗

<i>JAK2</i>Mutations in Myeloproliferative DisordersSemantic proximity Read ↗

How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusionsSemantic proximity Read ↗

Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working GroupSemantic proximity Read ↗

Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in OncologySemantic proximity Read ↗

A novel activating JAK1 mutation in chronic eosinophilic leukemia.Semantic proximity Read ↗

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutationSemantic proximity Read ↗

CUX1–PDGFRA: a novel fusion in myeloid/lymphoid neoplasms with eosinophiliaSemantic proximity Read ↗

PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocationSemantic proximity Read ↗

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway AlterationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.